用不同稳定剂涂覆豆蛋白的豆烯酸提取物的纳米脂体封装;表征和体外释放

相关实验视频

Updated: May 12, 2026

12:48

PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS

Published on: December 27, 2013

65.2K

Maedeh Parhizkary¹, Seid Mahdi Jafari^1,2, Elham Assadpour^3,4

¹Faculty of Food Science and Technology, Gorgan University of Agricultural Sciences and Natural Resources, Gorgan, Iran.

Food chemistry: X

|September 16, 2024

概括

使用豆蛋白分离物 (PPI) 覆盖的纳米脂质体 (NLs) 进行柔果提取物 (JE) 的纳米封装,可提高有益的化合物的稳定性和生物可用性. 这一创新提供了一个有前途的策略,用于纳入朱果.

科学领域:

食品科学与技术食品科学与技术
营养保健品营养保健品
在食品中纳米技术.

背景情况:

朱 (Ziziphus jujuba) 富含具有显著抗氧化,抗癌和抗炎性能的化合物.
不稳定性和低度的果基因限制了它们在功能性食品中的应用.
需要有效的方法来稳定和提高这些生物活性化合物的生物可用性.

研究的目的:

通过使用涂有豆蛋白分离物 (PPI) 的纳米脂质体 (NLs) 来研究豆提取物 (JE) 的纳米封装.
为了提高朱叶的稳定性和生物可用性.
评估纳米封装JE的抗氧化活性和受控释放.

主要方法:

通过乙醇注射方法制备纳米脂质体 (NLs).
用豆蛋白分离物 (PPI) 涂覆NLs.
使用动态光散射,多分散度指数和泽塔电位分析对NLs的表征.
在模拟的胃和肠液中评估抗氧化活性和体外释放特征.

主要成果:

使用PPI涂层NLs成功纳米封装朱提取物 (JE).
增强了封装JE的稳定性和改善了抗氧化活性.
在模拟的胃肠道条件下,证明了对JE的控制释放.
优化纳米脂质体特征 (大小,PDI,泽塔潜力).

结论:

豆蛋白分离物 (PPI) 覆盖的纳米脂质体 (NLs) 有效地稳定了朱果的基.
纳米封装显著增强了朱提取物 (JE) 的抗氧化活性和生物可用性.
这种方法提供了一个可行的策略,用于将果基因组合到功能性食品产品中.

关键词:

抗氧化剂是一种抗氧化剂.生物活性化合物生物活性化合物纳米载体的使用方法类化合物是一种类化合物.

相关概念视频

01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...

01:22

Modified-Release Drug Delivery Systems: Drug Release Characteristics

Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...

01:30

Modified-Release Drug Delivery Systems: Stimuli-Activated

Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...

01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...

01:11

Oral Drug Delivery Systems: Delayed-Release Systems

Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...